Does the media favor EYPT or VRCA?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 3 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Eyepoint Pharmaceuticals' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VNDA or VRCA?

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Vanda Pharmaceuticals' score of 0.35 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IKT or VRCA?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Inhibikase Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Inhibikase Therapeutics' score of 0.15 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRCA or AMRN?

In the previous week, Amarin had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Amarin and 3 mentions for Verrica Pharmaceuticals. Amarin's average media sentiment score of 0.86 beat Verrica Pharmaceuticals' score of 0.67 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRCA or ACB?

In the previous week, Aurora Cannabis had 23 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 26 mentions for Aurora Cannabis and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Aurora Cannabis' score of 0.15 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 5 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Verrica Pharmaceuticals (VRCA) Competitors

$4.11 -0.07 (-1.67%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.16 +0.05 (+1.17%)

As of 10/9/2026 07:00 PM Eastern

Compare

VRCA vs. EYPT, VNDA, IKT, AMRN, and ACB

Should you buy Verrica Pharmaceuticals stock or one of its competitors? Verrica Pharmaceuticals's main competitors and comparable companies include Eyepoint Pharmaceuticals (EYPT), Vanda Pharmaceuticals (VNDA), Inhibikase Therapeutics (IKT), Amarin (AMRN), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Verrica Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Verrica Pharmaceuticals has higher revenue and earnings than Eyepoint Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$2.79M	105.14	-$231.96M	-$3.74	N/A
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A

Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 655.88%. Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 208.19%. Given Eyepoint Pharmaceuticals' higher probable upside, equities analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Verrica Pharmaceuticals has a net margin of -102.84% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 3 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Eyepoint Pharmaceuticals' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Eyepoint Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Verrica Pharmaceuticals has a net margin of -102.84% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Vanda Pharmaceuticals' score of 0.35 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Verrica Pharmaceuticals has lower revenue, but higher earnings than Vanda Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.28	-$220.47M	-$4.63	N/A
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 186.29%. Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 208.19%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Vanda Pharmaceuticals and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 174.11%. Verrica Pharmaceuticals has a consensus price target of $12.67, suggesting a potential upside of 208.19%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Inhibikase Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inhibikase Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Inhibikase Therapeutics' return on equity of -42.80% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Inhibikase Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Inhibikase Therapeutics' score of 0.15 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,057.28	-$48.26M	-$0.43	N/A
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A

Summary

Verrica Pharmaceuticals beats Inhibikase Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Amarin?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Verrica Pharmaceuticals presently has a consensus target price of $12.67, suggesting a potential upside of 208.19%. Amarin has a consensus target price of $13.00, suggesting a potential upside of 8.06%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Verrica Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Amarin has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amarin has a net margin of -14.56% compared to Verrica Pharmaceuticals' net margin of -102.84%. Amarin's return on equity of -0.20% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Amarin	-14.56%	-0.20%	-0.14%

In the previous week, Amarin had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Amarin and 3 mentions for Verrica Pharmaceuticals. Amarin's average media sentiment score of 0.86 beat Verrica Pharmaceuticals' score of 0.67 indicating that Amarin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A

Summary

Verrica Pharmaceuticals beats Amarin on 9 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Verrica Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Verrica Pharmaceuticals has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	1.98	-$17.89M	-$1.67	N/A
Aurora Cannabis	$247.82M	1.19	-$88.13M	-$1.41	N/A

In the previous week, Aurora Cannabis had 23 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 26 mentions for Aurora Cannabis and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Aurora Cannabis' score of 0.15 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	5 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aurora Cannabis has a net margin of -32.26% compared to Verrica Pharmaceuticals' net margin of -102.84%. Aurora Cannabis' return on equity of 4.37% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Aurora Cannabis	-32.26%	4.37%	3.45%

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Verrica Pharmaceuticals currently has a consensus price target of $12.67, indicating a potential upside of 208.19%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Verrica Pharmaceuticals beats Aurora Cannabis on 9 of the 16 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.81M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-2.46	797.58	274.15	26.16
Price / Sales	1.98	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	2.65	10.71	11.21	6.34
Net Income	-$17.89M	$2.84B	$3.50B	$381.90M
7 Day Performance	-6.16%	-0.93%	-0.90%	-1.41%
1 Month Performance	-16.97%	-4.91%	-4.44%	-3.48%
1 Year Performance	-0.72%	-4.13%	6.96%	1.16%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	3.9287 of 5 stars	$4.11 -1.7%	$12.67 +208.2%	-4.4%	$71.81M	$35.58M	N/A	76	Gap Up
EYPT Eyepoint Pharmaceuticals	2.4243 of 5 stars	$3.15 -3.1%	$25.70 +715.9%	-75.7%	$280.19M	$31.37M	N/A	214
VNDA Vanda Pharmaceuticals	3.7302 of 5 stars	$4.58 -1.1%	$13.08 +185.7%	-16.1%	$279.94M	$216.10M	N/A	533	News Coverage Analyst Downgrade
IKT Inhibikase Therapeutics	1.9956 of 5 stars	$2.00 flat	$5.40 +170.0%	+18.7%	$279.07M	$260K	N/A	35
AMRN Amarin	1.5742 of 5 stars	$12.09 -2.1%	$13.00 +7.5%	-36.9%	$260.87M	$213.65M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. EYPT, VNDA, IKT, AMRN, and ACB

How does Verrica Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Summary

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. EYPT, VNDA, IKT, AMRN, and ACB

How does Verrica Pharmaceuticals compare to Eyepoint Pharmaceuticals?

Which has better earnings and valuation, EYPT or VRCA?

Do analysts rate EYPT or VRCA?

Is EYPT or VRCA more profitable?

Does the media favor EYPT or VRCA?

Which has more risk and volatility, EYPT or VRCA?

Do institutionals & insiders believe in EYPT or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Is VNDA or VRCA more profitable?

Does the media favor VNDA or VRCA?

Which has more volatility & risk, VNDA or VRCA?

Which has preferable earnings & valuation, VNDA or VRCA?

Do insiders and institutionals believe in VNDA or VRCA?

Do analysts recommend VNDA or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Inhibikase Therapeutics?

Do analysts prefer IKT or VRCA?

Which has more risk & volatility, IKT or VRCA?

Do insiders & institutionals believe in IKT or VRCA?

Is IKT or VRCA more profitable?

Does the media favor IKT or VRCA?

Which has preferable valuation and earnings, IKT or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Do analysts recommend VRCA or AMRN?

Which has more volatility and risk, VRCA or AMRN?

Do institutionals and insiders have more ownership in VRCA or AMRN?

Is VRCA or AMRN more profitable?

Does the media refer more to VRCA or AMRN?

Which has stronger earnings & valuation, VRCA or AMRN?

Summary

How does Verrica Pharmaceuticals compare to Aurora Cannabis?

Which has more volatility and risk, VRCA or ACB?

Which has preferable earnings and valuation, VRCA or ACB?

Does the media prefer VRCA or ACB?

Is VRCA or ACB more profitable?

Do institutionals & insiders believe in VRCA or ACB?

Do analysts rate VRCA or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools